INVA Research and Charts

INVA - Innoviva Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2024-08-12 (Delayed quote data 2025-01-03)

Last 17.52	Change ⇑ +0.12 (+0.69%)	Volume 603,574
	Open 17.41	High 17.78	Low 17.40

8EMA (Daily) 17.59	40EMA (Daily) 18.49	50EMA (Daily) 18.61	STO (Daily) 7.867	MACD Hist (Daily) -0.080
8EMA (Weekly) 18.311	40EMA (Weekly) 17.83	50EMA (Weekly) 17.47	STO (Weekly) 8.400	MACD Hist (Weekly) -0.710


Company Profile
Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.